Washington, DC (March 11, 2019) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement today regarding President Trump’s FY 2020 budget proposal:

The Biotechnology Innovation Organization (BIO) released the following statement on the action taken today by the U.S. Food & Drug Administration (FDA) which will allow AquaBounty Technologies, an American company, to commercialize its genetically engineered AquAdvantage® Salmon in the U.S. market.

The Biotechnology Innovation Organization (BIO) today released the following statement in response to the release of The Bioeconomy Initiative: Implementation Framework, a multi-agency strategy aimed at accelerating innovative technologies that harness the nation’s biomass resources for affordable biofuels, bioproducts, and biopower:

BIO President and CEO Jim Greenwood released the following statement on U.S. Trade Representative Robert Lighthizer’s testimony at a House Ways and Means Committee hearing on the U.S.-China trade deal and U.S. Secretary of Agriculture Sonny Perdue’s testimony at a House Agriculture Committee hearing on the state of the rural economy.  

Washington, DC (February 20, 2019) – The Biotechnology Innovation Organization (BIO) announced today it will join the Taiwan Bio-Industry Organization (Taiwan BIO) to host BIO Asia-Taiwan from July 24-28 in Taipei, Taiwan. The event is expected to attract more than 1,500 people from 25 countries representing biomedical, pharmaceutical, genomics, biotech services, equipment and instruments, academic research, cosmetology products and bio-based healthcare. Themed “Biotech as the Next Growth Engine for Asia”, the five-day event will feature rich programming, company presentations from Asia and around the world, BIO One-on-One Partnering™ meetings, seminars and workshops, and an exhibition featuring more than 1,700 booths from over 600 companies. “Taiwan is already a global powerhouse in technology, IT and computing systems,” noted Jim Greenwood, President and CEO of BIO. “As biotech evolves, we are marrying new breakthroughs like artificial intelligence with Big Data derived from the human genome. That’s why Taiwan is uniquely situated to play an integral role in the future of our industry.” Johnsee Lee, Chairman of the BIO Asia-Taiwan 2019 Organizing Committee agreed with this analysis. “As many innovative biomedical advances in the future will be closely integrated with digital technologies, and with the ICT industry being a unique advantage of Taiwan, this year's BIO Asia-Taiwan conference will showcase Taiwan's digital advantage in this sector,” he noted. “Applications such as AI, smart hospital and medical devices, precision medicine, etc., will be showcased as Taiwan takes the opportunity to encourage its electronics industry leaders to invest resources in biotech.” BIO’s One-on-One Partnering™, a major feature at the conference, will offer attendees a user-friendly way to schedule individual meetings with potential partners or collaborators by accessing a database with abundant profiles and other information. Meetings can be arranged prior…

BIO Executive Vice President for Health Policy Dan Durham issued the following statement regarding the CMS proposed decision memo for the CAR-T National Coverage Determination.

The Biotechnology Innovation Organization (BIO) applauds Sens. Thom Tillis (R-NC), Kyrsten Sinema (D-AZ), Gary Peters (D-MI), and David Perdue (R-GA) for introducing the Fostering Innovation Act (S.452) to build on the success of the Jumpstart Our Business Startups (JOBS) Act.